SG11202005510SA - Therapeutic enzyme fusion protein having a novel structure and use thereof - Google Patents
Therapeutic enzyme fusion protein having a novel structure and use thereofInfo
- Publication number
- SG11202005510SA SG11202005510SA SG11202005510SA SG11202005510SA SG11202005510SA SG 11202005510S A SG11202005510S A SG 11202005510SA SG 11202005510S A SG11202005510S A SG 11202005510SA SG 11202005510S A SG11202005510S A SG 11202005510SA SG 11202005510S A SG11202005510S A SG 11202005510SA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion protein
- novel structure
- enzyme fusion
- therapeutic enzyme
- therapeutic
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170178378 | 2017-12-22 | ||
| PCT/KR2018/016487 WO2019125059A1 (en) | 2017-12-22 | 2018-12-21 | Therapeutic enzyme fusion protein having novel structure and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005510SA true SG11202005510SA (en) | 2020-07-29 |
Family
ID=66993643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005510SA SG11202005510SA (en) | 2017-12-22 | 2018-12-21 | Therapeutic enzyme fusion protein having a novel structure and use thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210009984A1 (en) |
| EP (1) | EP3708661A4 (en) |
| JP (1) | JP7403455B2 (en) |
| KR (2) | KR102588611B1 (en) |
| CN (1) | CN111511910A (en) |
| AR (1) | AR113430A1 (en) |
| AU (1) | AU2018388331A1 (en) |
| BR (1) | BR112020012346A2 (en) |
| CA (1) | CA3086474A1 (en) |
| EA (1) | EA202091239A1 (en) |
| IL (1) | IL275248A (en) |
| MX (1) | MX2020006635A (en) |
| PH (1) | PH12020550927A1 (en) |
| SG (1) | SG11202005510SA (en) |
| TW (1) | TW201934753A (en) |
| WO (1) | WO2019125059A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111511910A (en) | 2017-12-22 | 2020-08-07 | 韩美药品株式会社 | Therapeutic enzyme fusion proteins with novel structures and uses thereof |
| EP3895708A3 (en) * | 2019-08-07 | 2022-01-19 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having a mutation in the gla gene |
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| CN116419759A (en) * | 2020-11-13 | 2023-07-11 | 韩美药品株式会社 | Use of therapeutic enzyme fusion proteins for the prevention and treatment of neurological disorders caused by or associated with fabry disease |
| KR20220065719A (en) * | 2020-11-13 | 2022-05-20 | 한미약품 주식회사 | Use of an enzyme fusion protein for prevention or treatment of renal disease |
| KR20230134822A (en) * | 2022-03-15 | 2023-09-22 | 주식회사 녹십자 | Liquid Formulation comprising a fusion protein including α-galactosidase A |
| KR20230134823A (en) * | 2022-03-15 | 2023-09-22 | 주식회사 녹십자 | Lyophilized formulation comprising a fusion protein including α-galactosidase A |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69309472T2 (en) | 1992-01-23 | 1997-10-23 | Merck Patent Gmbh, 64293 Darmstadt | FUSION PROTEINS OF MONOMERS AND DIMERS OF ANTIBODY FRAGMENTS |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| HUP0500423A2 (en) * | 1999-09-17 | 2005-08-29 | Gtc Biotherapeutics, Inc. | Transgenically produced fusion proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| WO2006108586A2 (en) * | 2005-04-11 | 2006-10-19 | Sanofi Pasteur | Polymyxin b analogs for lps detoxification |
| ATE509954T1 (en) * | 2005-12-30 | 2011-06-15 | Merck Patent Gmbh | ANTI-CD19 ANTIBODIES WITH REDUCED IMMUNOGENICITY |
| CN101687933B (en) * | 2007-05-30 | 2015-11-25 | 浦项工科大学校产学协力团 | Domain-immunoglobulin fusion proteins |
| WO2015009052A1 (en) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | Fusion protein of immunoglobulin hybrid fc and enzyme |
| IL243690B (en) * | 2013-07-31 | 2022-09-01 | Amgen Inc | Stabilization of fc containing polypeptides |
| EA035527B1 (en) | 2014-12-30 | 2020-06-30 | Ханми Фарм. Ко., Лтд. | Glucagon derivatives with improved stability |
| JP7320944B2 (en) * | 2015-10-08 | 2023-08-04 | マクロジェニクス，インコーポレーテッド | Molecules that specifically bind to B7-H3 and molecules that specifically bind to PD-1 |
| DK3386534T3 (en) * | 2015-12-08 | 2020-11-30 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| AR107483A1 (en) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | CONJUGATE OF THERAPEUTIC ENZYMES |
| IL271837B2 (en) * | 2017-07-07 | 2024-01-01 | Hanmi Pharm Ind Co Ltd | Novel therapeutic enzyme fusion protein and use thereof |
| CN111511910A (en) | 2017-12-22 | 2020-08-07 | 韩美药品株式会社 | Therapeutic enzyme fusion proteins with novel structures and uses thereof |
-
2018
- 2018-12-21 CN CN201880083193.8A patent/CN111511910A/en active Pending
- 2018-12-21 WO PCT/KR2018/016487 patent/WO2019125059A1/en unknown
- 2018-12-21 CA CA3086474A patent/CA3086474A1/en active Pending
- 2018-12-21 EA EA202091239A patent/EA202091239A1/en unknown
- 2018-12-21 JP JP2020534256A patent/JP7403455B2/en active Active
- 2018-12-21 KR KR1020180167795A patent/KR102588611B1/en active Application Filing
- 2018-12-21 AR ARP180103796A patent/AR113430A1/en unknown
- 2018-12-21 MX MX2020006635A patent/MX2020006635A/en unknown
- 2018-12-21 SG SG11202005510SA patent/SG11202005510SA/en unknown
- 2018-12-21 US US16/955,525 patent/US20210009984A1/en active Pending
- 2018-12-21 AU AU2018388331A patent/AU2018388331A1/en active Pending
- 2018-12-21 BR BR112020012346-3A patent/BR112020012346A2/en unknown
- 2018-12-21 EP EP18891205.9A patent/EP3708661A4/en active Pending
- 2018-12-22 TW TW107146641A patent/TW201934753A/en unknown
-
2020
- 2020-06-09 IL IL275248A patent/IL275248A/en unknown
- 2020-06-17 PH PH12020550927A patent/PH12020550927A1/en unknown
-
2023
- 2023-10-04 KR KR1020230131722A patent/KR102712547B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL275248A (en) | 2020-07-30 |
| KR20190076909A (en) | 2019-07-02 |
| CA3086474A1 (en) | 2019-06-27 |
| KR102588611B1 (en) | 2023-10-16 |
| EA202091239A1 (en) | 2020-09-09 |
| PH12020550927A1 (en) | 2021-05-10 |
| NZ765453A (en) | 2024-03-22 |
| US20210009984A1 (en) | 2021-01-14 |
| KR20230143985A (en) | 2023-10-13 |
| KR102712547B1 (en) | 2024-10-04 |
| JP2021507705A (en) | 2021-02-25 |
| BR112020012346A2 (en) | 2020-11-24 |
| EP3708661A4 (en) | 2021-12-01 |
| AR113430A1 (en) | 2020-04-29 |
| EP3708661A1 (en) | 2020-09-16 |
| TW201934753A (en) | 2019-09-01 |
| CN111511910A (en) | 2020-08-07 |
| AU2018388331A1 (en) | 2020-07-02 |
| JP7403455B2 (en) | 2023-12-22 |
| WO2019125059A1 (en) | 2019-06-27 |
| MX2020006635A (en) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275248A (en) | Therapeutic enzyme fusion protein having a novel structure and use thereof | |
| EP3623389A4 (en) | Fusion protein containing tgf- receptor and medicinal uses thereof | |
| IL267861A (en) | A pd1-41bbl fusion protein and methods of use thereof | |
| IL273439A (en) | Fusion proteins comprising enzyme replacement therapy enzymes | |
| IL267862A (en) | A sirpalpha-41bbl fusion protein and methods of use thereof | |
| IL280102A (en) | Pd1-4-1bbl variant fusion protein and methods of use thereof | |
| ZA201900209B (en) | Novel natural protein and application thereof | |
| ZA202000595B (en) | Novel therapeutic enzyme fusion protein and use thereof | |
| EP3722305A4 (en) | Hm-3 fusion protein and use thereof | |
| SG11202104912SA (en) | Fusion protein and use thereof | |
| IL280103A (en) | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof | |
| SG11202110400QA (en) | Fusion protein and use thereof | |
| IL290660A (en) | Therapeutic fusion proteins | |
| EP3668551A4 (en) | Apom-fc fusion proteins and uses thereof | |
| EP3702362A4 (en) | Polypeptide having analgesic activity and use thereof | |
| IL272050B1 (en) | Synthetic proteins and therapeutic uses thereof | |
| EP3816181A4 (en) | Improved fviii fusion protein and use thereof | |
| EP3601572A4 (en) | Protein expression construct and methods thereof | |
| ZA201904386B (en) | S-arrestin peptides and therapeutic uses thereof | |
| HUP1700012A2 (en) | Novel proteins and use thereof | |
| IL292599A (en) | Tmem219 antibodies and therapeutic uses thereof | |
| EP3875483A4 (en) | Fusion protein comprising ids and use thereof | |
| HUE060194T2 (en) | Peptide derivatives and therapeutic activity thereof |